AXSOME THERAPEUTICS I

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

01 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

25 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

25 Mar 2024 05:30:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

19 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

05 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

27 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

20 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

12 Feb 2024 08:47:31 By NetDania Notify

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

09 Feb 2024 08:54:59 By NetDania Notify

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

08 Feb 2024 12:42:43 By NetDania Notify

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

06 Feb 2024 10:00:35 By NetDania Notify

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

24 Jan 2024 09:38:35 By NetDania Notify

Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20

23 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

10 Jan 2024 08:46:51 By NetDania Notify

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

04 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

11 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

07 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

22 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

21 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

06 Nov 2023 06:00:00 By Nasdaq GlobeNewswire